Shots:
- Oculis will acquire Accure’s worldwide development & commercial rights to Privosegtor (ACT-01), terminating its existing license & giving Oculis greater control and economic upside as the neuro-ophthalmology asset advances
- Deal also incl. ACT-02, a preclinical neurology candidate. Total consideration incl. $3.8M upfront cash & ~2.05M Oculis shares, incl. milestone-linked shares. Closing is expected by Feb 28. 2027 for ACT-01 and Mar 31, 2027 for ACT-02
- ACT-01 is a peptoid small molecule designed to cross the blood-brain & retinal barriers for potential neuroprotection in optic neuritis & other neuro-axonal diseases. Oculis is advancing PIONEER-1, with an IND submission for acute MS relapse planned for Q4’26
Ref: Globenewswire | Image: Oculis & Accure | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
